Table 3.
Sensitivity and specificity of published models for prediction of unilateral PA in our development or validation cohort.
| References | Model | Sample of Development Cohort | Sample of Validation Cohort | Sensitivity in Our Development Cohort | Specificity in Our Development Cohort |
|---|---|---|---|---|---|
| Holaj et al. SCORE [34] | Unilateral nodule ≥ 6 mm, PAC post-SIT > 16.5 ng/dL | UPA = 96 BPA = 54 |
UPA = 94 BPA = 44 |
48% | 100% |
| Kupers et al. [20] | Unilateral nodule ≥ 8 mm, serum K+ < 3.5 mmol/L and eGFR ≥ 100 | UPA = 49 BPA = 38 |
None | 51% | 89% |
| Nanba et al. [21] | PAC ≥ 16.5 ng/dL, ARR post-CCT ≥ 82, and K+ ≤ 3.4 mmol/L |
UPA = 32 BPA = 39 |
None | 40% | 87% |
| Kocjan [22] | K+ < 3.5 mmol/L, PAC post-SIT > 18 ng/dL and unilateral nodule “regardless of size” | UPA = 28 BPA = 39 |
None | 28% | 100% |
| Kamemura [23] | K+ < 3.5 mmol/L, unilateral nodule ≥ 8 mm, baseline ARR ≥ 55 and male sex | UPA = 24 BPA = 204 |
None | 20% | 96% |
| Kobayashi (JPAS) [24] | K+ < 3.5 mmol/L, baseline PAC ≥ 21.0 ng/dL, unilateral nodule ≥ 8 mm, baseline ARR ≥ 62 and male sex | UPA = 378 BPA = 912 | UPA = 202 BPA = 444 |
35% * 35% |
98% * 100% |
| Puar et al. [25] | PAC to lowest potassium ratio > 15 | UPA = 70 BPA = 33 |
UPA = 48 BPA = 44 |
50% | 78% |
| Burrello et al. (SPACE) [27] | Unilateral nodule ≥ 8 mm, lowest potassium ≤ 3.9 mmol/L, PAC post-CCT or SIT > 8.9 ng/dL and PAC at screening > 30.3 ng/dL |
UPA = 93 BPA = 57 |
UPA = 40 BPA = 25 |
40% * 40% |
98% * 100% |
| Lee et al. [28] | Serum K+ < 3.5 mmol/L, PAC > 30 ng/dL and unilateral lesion > 7 mm | UPA = 372 BPA = 39 | None | 38% | 93% |
| Young et al. [29] | Age < 40 and unilateral nodule > 10 mm | UPA = 102 BPA = 84 | None | 13% | 100% |
| Kaneko et al. [30] | PAC post-SIT > 13.1 ng/dL | UPA = 16 BPA = 48 |
None | 68% | 57% |
| Umakoshi et al. [31] | PAC > 15.9 ng/dL, serum, K+ < 3.5 mmol/L, unilateral nodule > 10 mm and age < 35 years | UPA = 258 BPA = 96 | None | 4% | 100% |
| Rossi et al. [32] | Age < 45 years, K+ < 3.6 mmol/L, unilateral nodule ≥ 5 mm | UPA = 131 BPA = 100 | None | 14% | 98% |
| References | Model | Sample of Development Cohort | Sample of Validation Cohort | Sensitivity in Our Validation Cohort | Specificity in Our Validation Cohort |
| Holaj et al. SCORE [34] | Unilateral nodule ≥ 6 mm, PAC post-SIT > 16.5 ng/dL | UPA = 96 BPA = 54 |
UPA = 94 BPA = 44 |
** 36% | ** 100% |
| Song et al. (CONPASS) [33] | PAC > 20.0 ng/dL, K+ ≤ 3.5 mmol/L, PRC ≤ 5 μIU/mL, unilateral nodule ≥ 10 mm | UPA = 268 BPA = 88 | UPA = 84 BPA = 117 |
** 35% | ** 89% |
ARR, aldosterone-to-renin ratio; BPA, bilateral adrenal hyperplasia; CCT, captopril challenge test; eGFR, estimated glomerular filtration rate; NA, not applicable; PAC, plasma aldosterone concentration; PRC, plasma renin concentration; SIT, saline infusion test; UPA, unilateral primary aldosteronism. * after exclusion of one falsely classified patient; ** sensitivity and specificity in our validation cohort.